Counsel Allison Glasunow is experienced in patent preparation and prosecution in U.S. and foreign jurisdictions, post-grant review procedures at the U.S. Patent and Trademark Office (USPTO), freedom to operate analysis, and patent landscape analysis. Allison counsels clients on technical and legal matters concerning patentability and strategy to develop their patent portfolios. Her background includes patent matters involving clinical trials and product approvals at the Food and Drug Administration (FDA). In addition, Allison assists with due diligence and patent litigation matters.
Life science matters are a major focus of her patent practice. Allison has practice depth in immunotherapy, genetics and genomics, stem cells, cancer therapies, cardiovascular therapies, clinical and research diagnostics, pharmaceuticals, and medical devices, among others. Specific examples of technologies that Allison has experience with include the following: cellular immunotherapy, such as chimeric antigen receptor “CAR” T-cells, antibodies, and antibody drug conjugates; sequencing technologies, such as high-throughput sequencing and next generation sequencing (NGS); gene editing technologies, such as CRISPER/Cas9; nucleic acid delivery technologies, such as engineered vectors and siRNA/RNAi; checkpoint inhibitors; fatty acids; and neurostimulation and neurovascular interventional therapies.
Allison’s graduate research at the University of Washington School of Medicine focused on cellular behavior and genetics underlying cardiovascular disease. As a Ph.D. candidate, Allison was an American Heart Association Fellow and recognized several times for excellence in cardiovascular research. As a post-doctoral Ph.D. fellow at the Ben Towne Center for Childhood Cancer Research at the Seattle Children’s Research Institute, Allison developed a set of molecular tools useful for cancer immunotherapies, and in particular, chimeric antigen receptor (CAR) modified T cells. She has published several research articles and presented her work before dozens of audiences in the United States and internationally.